News

The Morning Bull - US Market Morning Update Wednesday, Sep, 2 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.5%. The key pressure is coming from a broad selloff in global stocks as investors react to rising government bond yields, including euro area and UK 10 year benchmarks, where inflation concerns are lifting expected interest rates. At the same time, global manufacturing scorecards such as the euro area PMI at 52.7 and Germany at 54.3...

The State Street SPDR S&P Biotech ETF is up 33% this year, but fund flows remain muted.

In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...

None of the underlying conditions that sent Sandisk to its all-time high earlier this year have changed.

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.

Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.

The company progresses its mRNA-based candidate just under a month after Moderna won FDA approval for the first seasonal flu mRNA vaccine.

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Moderna stock led the index after melanoma vaccine data, while a hedge fund's forced unwind turbocharged a rebound in enterprise software

The company may be on track to its next product.

Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]

Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.

August was good to U.S. stock investors. All three major U.S. indexes are on track to finish the month in the green—something that has happened since May. The tech-focused Nasdaq is leading the way, up about 4.

August turned out to be a pretty good month for S&P 500 investors. And some stocks wound up having a great month.

August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least. The former’s stock closed 12.6% higher and the latter’s stock closed 176% higher on August 19th. The stocks surged after a major announcement from Moderna Inc. (NASDAQ:MRNA) shared the results from its […]

Legendary singer and actress Dolly Parton passed away on Tuesday at the age of 80. While she was best known for her role in shaping global entertainment and, to many, as the “Queen of Country,” Parton leaves behind one of...

Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.

Merck (NYSE:MRK) and Moderna report the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The therapy was tested in combination with Merck's immunotherapy KEYTRUDA in a Phase 3 trial setting. This marks the first time an mRNA-based individualized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer. The result signals a potential new path for personalized cancer vaccines with...

The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna Inc. (NASDAQ:MRNA) and Merck […]

Moderna (NasdaqGS:MRNA) received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant. The FDA also cleared mFlusiva, Moderna's first mRNA based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA authorized mRNA flu shot for older adults. To see how other companies in this space are using similar technology, explore 39 healthcare AI...

A woman with nearly $2 million saved sold her biotech shares when her boyfriend pressured her, watched the stock explode the next day, and then got dumped for it. Suze Orman had something to say about who actually came out ahead.

Moderna, Inc. (NASDAQ:MRNA) proposed a private placement of $2.0 billion in convertible senior notes due in 2032, with an option for initial purchasers to acquire another $300 million. The notes would be senior unsecured obligations, carry no regular interest, and have no principal accretion. Net proceeds would pay for capped-call transactions and support general corporate […]

For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. The pharma industry is entering its biggest wave of patent expirations in decades. The world’s bestselling drug in 2025, Merck’s cancer immunotherapy Keytruda, loses U.S. patent protection in 2028, and nearly every pharma company has at least one blockbuster drug that will go off patent in the next five years.

On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replied: Here’s what I would do: I think that you have to […]

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers.

BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical

BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients.

On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said that their personalized mRNA cancer vaccine, combined with Merck’s Keytruda, met its main goals in a first-ever Phase 3 trial for melanoma. The news sent Moderna shares up as much as 177%, adding $44 billion to its market value, while Merck […]

On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said their personalized melanoma vaccine, intismeran, combined with Merck’s Keytruda, met its goals in a Phase 3 trial of 1,137 patients. It reduced the risk of cancer recurrence and spread compared with Keytruda alone, Reuters reported. It is the first positive late-stage […]

BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.